News about Global Pharma

Kincell Bio Appoints New Chief Executive Officer to Drive Business Growth

Mark, who has served as Chair of the Board since May 2024, brings decades of industry experience to the role and will be pivotal in advancing Kincell Bio’s mission to support innovators in the rapidly growing cell therapy sector.

Global Pharma | 21/01/2025 | By Aishwarya |  276

Zydus Lifesciences Gets USFDA Nod for Phase II(b) Trial of Usnoflast in ALS

Zydus has received USFDA approval to conduct a Phase II(b) clinical trial for Usnoflast, an oral NLRP3 inflammasome inhibitor, in Amyotrophic Lateral Sclerosis (ALS) patients.

Global Pharma | 20/01/2025 | By Manvi |  616

Fermion Partners with Simcere to Develop China's First SSTR4 Agonist Targeting Pain

Guangzhou Fermion Technology and Simcere Pharmaceutical have partnered to develop and commercialise FZ002-037, a clinical-stage SSTR4 agonist for pain management, marking China's first and the world's second selective SSTR4 agonist to reach this stage.

Global Pharma | 20/01/2025 | By Manvi |  700

Glenmark Life Sciences Rebrands its Identity as Alivus Life Sciences

The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus.

Global Pharma | 20/01/2025 | By Aishwarya |  3427

India Restricts Import of Refurbished Medical Devices Due to Regulatory Gaps

This move highlights India's stringent approach toward medical device regulation, ensuring that only new, certified devices meeting quality and safety standards enter the market.

Global Pharma | 20/01/2025 | By Aishwarya |  651

Freudenberg Medical Announces Appointment of Michael McGee as New CEO

Michael McGee, former COO, assumed the role of Chief Executive Officer, succeeding Dr. Mark Ostwald, who transitioned to another leadership role within the Freudenberg Group.

Global Pharma | 20/01/2025 | By Aishwarya |  314

MalarVx Partners with HDT Bio to Advance repRNA/LION Malaria Vaccine Technology

MalarVx, Inc. has licensed HDT Bio's self-amplifying replicon RNA and LION technologies to develop potent, durable, and cost-effective malaria vaccines.

Global Pharma | 18/01/2025 | By Manvi |  259

Concord Biotech to Use Renewable Energy in its Dholka Facility to Promote Sustainability

Ahmedabad-based pharmaceutical company Concord Biotech will procure 9.9 MW wind-solar hybrid power from Clean Max Enviro Energy Solutions (CleanMax), marking its first investment in renewable energy to power its manufacturing plant at Dholka in Gujarat.

Global Pharma | 18/01/2025 | By Manvi |  694

Mytos Signs Manufacturing Deal with Aspen Neuroscience in Parkinson?s Disease

As part of the partnership agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing facility in Torrey Pines, Calif.

Global Pharma | 18/01/2025 | By Aishwarya |  259

SCHOTT Pharma Introduces Next Gen Polymer Syringe System

Developed with SCHOTT Pharma's Alliance to Zero partners, Schreiner MediPharm and Körber Pharma, the system consists of a new cap, a functional label, and a carton packaging.

Global Pharma | 18/01/2025 | By Aishwarya |  398